术后肌少症的发展是食管胃结合部腺癌和胃上部癌患者预后不良的强有力预测指标。
Postoperative development of sarcopenia is a strong predictor of a poor prognosis in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer.
机构信息
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Endoscopy and Endoscopic Surgery, Fukuoka Dental College, Fukuoka, Japan.
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
出版信息
Am J Surg. 2019 Apr;217(4):757-763. doi: 10.1016/j.amjsurg.2018.07.003. Epub 2018 Jul 10.
BACKGROUND
There were few studies assessed the postoperative sarcopenia in patients with cancers. The objective of present study was to assess whether postoperative development of sarcopenia could predict a poor prognosis in patients with adenocarcinoma of esophagogastric junction, (AEG) and upper gastric cancer (UGC).
METHODS
Patients with AEG and UGC who were judged as non-sarcopenic before surgery were reassessed the presence of postoperative development of sarcopenia 6 months after surgery. Patients were divided into the development group or non-development group, and clinicopathological factors and prognosis between these two groups were analyzed.
RESULTS
The 5-year overall survival rates were significantly poorer in the development group than non-development group (68.0% vs. 92.6%, P = 0.0118). Multivariate analyses showed that postoperative development of sarcopenia was an independent prognostic factor for poor overall survival (P = 0.0237).
CONCLUSIONS
Postoperative development of sarcopenia was associated with a poor prognosis in patients with AEG and UGC.
背景
目前很少有研究评估癌症患者术后肌少症的情况。本研究旨在评估胃食管结合部腺癌（AEG）和胃上部癌（UGC）患者术后是否会发生肌少症，以及其是否能预测预后不良。
方法
对术前未发生肌少症的 AEG 和 UGC 患者在术后 6 个月时重新评估是否出现术后肌少症的发生。将患者分为发生组和未发生组，分析两组之间的临床病理因素和预后情况。
结果
发生组的 5 年总生存率明显低于未发生组（68.0% vs. 92.6%，P=0.0118）。多因素分析显示，术后肌少症的发生是总生存不良的独立预后因素（P=0.0237）。
结论
AEG 和 UGC 患者术后肌少症的发生与预后不良相关。
Zotero 插件